---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-173521"
form_type: "8-K"
ticker: "RMD"
cik: "0000943819"
company_name: "RESMED INC"
filed_at: "2022-06-14T23:59:59+00:00"
generated_at: "2026-06-25T02:12:27.898098+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# ResMed to acquire German out-of-hospital software leader MEDIFOX DAN for ~$1B

## Summary
- Purchase price ~US$1.0B (€950M); expected to close by Dec 31, 2022 subject to German regulatory clearances.
- MEDIFOX DAN CY2021 pro forma revenue ~$83M, adjusted EBITDA ~$35M; deal expected accretive to non-GAAP EPS.
- Expands ResMed's SaaS business into Germany; MEDIFOX DAN brand and management to continue under ResMed SaaS.
- Co-managing directors Dr. Thorsten Schliebe and Christian Städtler will remain, reporting to ResMed SaaS President.
- ResMed to fund via existing credit facilities; Evercore and DLA Piper serving as advisors.

## SEC filing metadata
- accession: 0001193125-22-173521
- form_type: 8-K
- ticker: RMD
- cik: 0000943819
- company_name: RESMED INC
- filed_at: 2022-06-14T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/943819/000119312522173521/0001193125-22-173521-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/943819/000119312522173521/d366389d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-173521
- JSON: https://secwatch.observer/filing/0001193125-22-173521.json
- Plain text: https://secwatch.observer/filing/0001193125-22-173521.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.